Financial Reports Latest Updates Industry Maps Economic Calendar

Karyopharm Therapeutics Inc. (KPTI) Annual Reports

Q: Where can I read Karyopharm Therapeutics Inc. (KPTI) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Karyopharm Therapeutics Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1503802 →

Website：Official site ↗

Financial Highlights

FY2026 Q2 (quarterly, ended 2026-06-30)
	Current	Prior year	YoY
Revenue	$33.4M	$37.9M	-11.9%
Operating income	$-22.5M	$-24.4M	+7.6%
Net income	$-67.0M	$-37.3M	-79.9%
EPS (diluted)	$-2.32	$-4.32	+46.3%

Company guidance
	Period	Range
Revenue	FY2026	$130M – $150M

Figures are the company’s own outlook as stated in its earnings release, not analyst estimates.

Source: SEC EDGAR (XBRL company facts); guidance from Form 8-K Exhibit 99.1

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 33.4 mn Net income -67.0 mn

Show table：Income statement

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q2	2013Q3	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Revenue	0.15	0.03	0.53	0.03	0.03	0.23	0.13	1.25	0.02	0.17	0.02	0.02	0.02	—	0.15	0.08	0.03	—	0.06	0.05	0.05	0.07	0	0	1.53	10.0	19.9	0.24	0.21	0.16	9.49	13.2	18.1	18.1	33.5	21.3	35.1	23.3	22.6	37.7	126	47.7	39.7	36.1	33.6	38.7	37.6	36.0	33.8	33.1	42.8	38.8	30.5	30.0	37.9	44.0	34.1	35.1	33.4
Operating income	-10.3	-3.98	-4.03	-3.63	-4.24	-5.61	-6.87	-9.32	-12.2	-13.7	-16.4	-19.7	-25.9	-26.1	-33.0	-30.6	-29.3	-27.4	-30.5	-25.7	-27.2	-30.3	-29.8	-31.1	-39.5	-38.9	-34.3	-49.1	-57.5	-64.9	-41.7	-39.4	-43.3	-47.4	-40.3	-47.1	-37.1	-52.4	-49.0	-43.8	47.0	-34.6	-42.9	-30.8	-33.9	-30.9	-29.6	-31.3	-37.8	-33.8	-28.1	-26.3	-31.3	-33.3	-24.4	-15.2	-17.8	-26.8	-22.5
Net income	—	—	—	—	-15.9	—	—	—	-34.0	-13.7	-16.4	-19.7	-25.9	-26.1	-32.7	-30.4	-29.1	-27.1	-30.2	-25.4	-26.9	-29.9	-29.4	-30.6	-39.0	-38.5	-33.6	-48.1	-58.2	-66.2	-43.4	-41.4	-48.6	-52.9	-46.4	-53.5	-43.4	-57.4	-53.6	-51.8	38.7	-41.4	-49.1	-36.3	-38.5	-34.1	-32.6	-34.5	-41.8	-37.4	23.8	-32.1	-30.8	-23.5	-37.3	-33.1	-102	-22.4	-67.0

Balance sheet

Quarterly · In mn (USD)

Total assets 111 mn Total liabilities 441 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q2	2013Q3	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Current assets	—	—	—	—	0.95	—	—	53.6	158	148	135	231	208	249	225	198	178	138	124	130	132	112	146	122	148	133	245	212	335	271	223	281	279	371	318	285	277	256	274	242	276	277	242	223	350	319	291	263	234	198	209	185	156	120	97.9	89.8	103	126	106
Total assets	—	—	—	—	1.31	—	—	55.9	158	149	138	235	220	292	263	237	215	192	171	184	180	155	186	164	180	146	257	220	341	287	238	298	295	416	380	338	313	275	287	254	305	294	256	231	358	326	298	270	240	204	214	189	164	128	105	96.2	108	131	111
Current liabilities	—	—	—	—	1.93	—	—	4.00	3.29	5.01	5.65	6.23	12.3	14.7	14.1	14.4	15.1	13.2	15.5	14.9	16.5	15.5	17.5	21.2	49.5	46.7	36.5	41.6	46.9	43.9	32.2	39.2	46.4	49.7	50.6	52.6	60.2	62.0	58.1	68.9	73.7	66.3	62.5	61.8	65.9	61.6	58.9	62.1	69.5	65.3	57.6	61.5	92.3	90.4	99.2	87.2	92.1	117	134
Total liabilities	—	—	—	—	—	—	—	—	3.29	—	6.00	7.35	13.5	16.5	16.0	16.4	17.1	15.1	17.3	16.7	18.1	17.1	19.0	22.6	50.8	50.8	43.1	48.9	158	166	156	238	245	250	250	254	263	315	370	380	385	377	373	372	375	371	369	370	377	373	346	349	350	334	344	365	401	397	441
Equity	-12.7	—	—	—	-27.9	—	—	-47.8	155	144	132	228	207	276	247	221	198	177	154	167	162	138	167	141	129	95.5	213	171	183	121	82.5	59.9	49.8	166	130	83.8	50.5	-39.6	-83.1	-126	-79.7	-83.1	-116	-140	-16.7	-45.2	-71.3	-100	-136	-169	-132	-160	-186	-206	-239	-269	-293	-266	-330

Cash flow

Quarterly · In mn (USD)

Operating -24.9 mn Investing -10.0 mn Financing -0.9 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q2	2013Q3	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating	-8.55	—	—	-11.5	-3.98	-5.16	-6.16	-45.7	-10.1	-10.6	-11.9	-16.2	-12.8	-20.2	-28.1	-25.3	-20.4	-23.2	-20.9	-20.3	-20.0	-24.7	-21.7	-21.8	-5.54	-34.6	-37.6	-38.7	-48.2	-66.6	-48.2	-36.5	-39.5	-45.0	-40.3	-44.3	-30.6	-52.9	-55.8	-23.9	25.5	-59.2	-35.1	-28.4	-26.8	-18.9	-25.7	-29.5	-18.6	-43.7	-38.5	-19.4	-25.8	-39.0	-18.7	-5.86	-11.8	-22.7	-24.9
Investing	-0.38	—	—	-0.12	0	—	—	-0.56	-0.03	-0.52	-0.32	-2.29	-63.9	-170	0.86	44.6	33.8	6.75	16.2	-4.97	6.60	0.55	-1.13	20.6	-2.90	2.48	-27.6	20.6	-103	32.0	39.8	40.2	-33.5	-46.5	-60.0	21.4	31.4	43.2	46.5	21.4	30.8	-14.0	-36.6	11.7	-65.3	-32.4	21.2	-7.68	26.8	21.9	51.3	7.47	14.8	15.3	18.3	4.81	5.00	3.20	-10.0
Financing	12.0	—	—	7.01	2.50	5.53	23.1	99.2	113	0.01	-0.38	113	0.15	91.2	0.02	0.04	1.48	0.2	0.24	31.5	19.3	0.06	52.6	0.16	23.0	0.43	147	0.77	168	0.15	0.4	88.8	34.9	165	2.05	1.24	3.97	10.7	62.1	0.02	0.9	30.8	1.31	5.80	156	0	0.86	0	0.26	—	41.0	0	0.68	0	0.36	0	29.7	49.8	-0.9
Cash at period end	6.51	—	—	1.87	0.39	0.76	17.7	52.9	156	145	132	227	151	51.5	24.2	43.5	58.4	42.2	37.7	43.9	49.7	25.6	55.4	54.5	69.0	37.5	119	102	118	83.5	75.5	168	129	202	103	82.3	85.9	88.5	141	137	190	153	82.3	71.3	135	84.1	80.9	43.7	52.2	30.6	84.8	72.8	62.5	38.8	38.7	37.7	60.5	90.8	55.0

Profitability

Quarterly · %

Operating margin -67.4% Net margin -200.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q2	2013Q3	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
Operating margin	-6783.6%	-11714.7%	-756.9%	-10691.2%	-12842.4%	-2408.2%	-5165.4%	-748.7%	-57847.6%	-8018.7%	-78323.8%	-94019.1%	-162137.5%	—	-22008.7%	-40813.3%	-117212.0%	—	-51654.2%	-53629.2%	-57797.9%	-44527.9%	-991733.3%	—	-2571.8%	-389.4%	-172.6%	-20566.5%	-27890.8%	-41885.2%	-439.1%	-299.6%	-239.1%	-261.1%	-120.3%	-220.8%	-105.6%	-225.2%	-217.0%	-116.3%	37.2%	-72.5%	-108.1%	-85.3%	-100.9%	-79.8%	-78.7%	-86.8%	-112.0%	-101.9%	-65.7%	-67.8%	-102.4%	-110.8%	-64.3%	-34.6%	-52.4%	-76.3%	-67.4%
Net margin	—	—	—	—	-48145.4%	—	—	—	-161652.4%	-8008.2%	-78242.9%	-93923.8%	-162050.0%	—	-21796.7%	-40497.3%	-116184.0%	—	-51115.3%	-52968.8%	-57308.5%	-43995.6%	-979566.7%	—	-2545.0%	-384.6%	-169.2%	-20118.4%	-28257.3%	-42684.5%	-457.3%	-314.6%	-268.8%	-291.8%	-138.5%	-250.8%	-123.7%	-246.8%	-237.1%	-137.5%	30.7%	-86.8%	-123.7%	-100.5%	-114.7%	-88.2%	-86.8%	-95.8%	-124.0%	-112.8%	55.6%	-82.7%	-100.8%	-78.2%	-98.2%	-75.2%	-299.9%	-63.9%	-200.5%

Returns & leverage

Quarterly · %

ROE -891.0% ROA -207.9% Debt ratio 396.6%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q2	2013Q3	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
ROE	—	—	—	—	—	—	—	—	—	—	—	-93.1%	-41.9%	-42.0%	-55.1%	-51.3%	-58.3%	-52.7%	-58.2%	-57.6%	-60.8%	-71.3%	-69.7%	-75.9%	-88.4%	-117.6%	-74.6%	-102.0%	-114.1%	-190.1%	-145.9%	-181.1%	-171.4%	-129.7%	-178.4%	-280.6%	-391.3%	-317.4%	-891.0%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
ROA	—	—	—	—	—	—	—	—	—	—	—	-57.6%	-40.0%	-40.0%	-52.1%	-48.7%	-54.2%	-49.2%	-53.7%	-53.1%	-55.4%	-64.7%	-62.6%	-67.3%	-71.5%	-91.1%	-64.1%	-83.0%	-68.4%	-95.1%	-87.3%	-80.8%	-62.8%	-53.0%	-61.3%	-63.4%	-64.6%	-58.1%	-62.4%	-69.7%	-40.1%	-38.0%	-38.1%	-36.3%	-49.8%	-51.0%	-51.1%	-55.8%	-47.8%	-55.2%	-35.1%	-38.1%	-37.8%	-37.6%	-77.5%	-87.2%	-143.7%	-150.5%	-207.9%
Debt ratio	—	—	—	—	—	—	—	—	2.1%	—	4.4%	3.1%	6.2%	5.7%	6.1%	6.9%	7.9%	7.9%	10.1%	9.1%	10.1%	11.0%	10.3%	13.8%	28.2%	34.7%	16.8%	22.2%	46.3%	57.8%	65.4%	79.9%	83.1%	60.1%	65.8%	75.2%	83.8%	114.4%	129.0%	149.6%	126.1%	128.3%	145.4%	160.7%	104.7%	113.9%	123.9%	137.2%	156.7%	182.6%	161.8%	184.3%	213.1%	261.2%	327.8%	379.8%	370.2%	302.1%	396.6%

EPS

Quarterly · US$

EPS US$-2.32

Show table：EPS

Item	2011Q4	2012Q1	2012Q2	2012Q3	2012Q4	2013Q2	2013Q3	2013Q4	2013Q4	2014Q4	2014Q2	2014Q3	2014Q4	2015Q1	2015Q2	2015Q3	2015Q4	2016Q1	2016Q2	2016Q3	2016Q4	2017Q1	2017Q2	2017Q3	2017Q4	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-2.72	—	-0.71	-0.69	0.52	-0.53	-0.62	-0.45	-0.42	-0.30	-0.29	-0.30	-0.36	-0.32	-0.20	-0.26	-0.24	-2.77	-4.32	-3.82	-7.00	-1.24	-2.32

Revenue & profit

Year-to-date · In mn (USD)

Revenue 68.5 mn Net income -89.4 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 111 mn Total liabilities 441 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -47.7 mn Investing -6.84 mn Financing 48.9 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -72.0% Net margin -130.5%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -891.0% ROA -207.9% Debt ratio 396.6%

EPS

Year-to-date · US$

EPS US$-3.56

Revenue & profit

Annual · In mn (USD)

Revenue 146 mn Net income -196 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2012	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	0.63	—	—	1.61	30.3	40.9	108	210	157	146	145	146
Operating income	-15.9	-119	-111	-131	-180	-189	-172	-98.3	-142	-130	-119	-90.7
Net income	—	-118	-110	-129	-178	-200	-196	-124	-165	-143	-76.4	-196

Balance sheet

Annual · In mn (USD)

Total assets 108 mn Total liabilities 401 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2012	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	0.95	178	132	148	335	279	277	276	350	234	156	103
Total assets	1.31	215	180	180	341	295	313	305	358	240	164	108
Current liabilities	1.93	15.1	16.5	49.5	46.9	46.4	60.2	73.7	65.9	69.5	92.3	92.1
Total liabilities	—	17.1	18.1	50.8	158	245	263	385	375	377	350	401
Equity	-27.9	198	162	129	183	49.8	50.5	-79.7	-16.7	-136	-186	-293

Cash flow

Annual · In mn (USD)

Operating -75.4 mn Investing 43.4 mn Financing 30.1 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2012	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-94.0	-84.4	-73.7	-159	-191	-160	-107	-150	-92.7	-127	-75.4
Investing	—	-90.8	24.6	17.1	-108	78.5	-53.7	142	-104	7.94	95.5	43.4
Financing	—	92.7	51.2	75.7	316	124	172	73.7	194	1.12	—	30.1
Cash at period end	0.39	58.4	49.7	69.0	118	129	85.9	190	135	52.2	62.5	60.5

Profitability

Annual · %

Operating margin -62.1% Net margin -134.2%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2012	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	-2506.3%	—	—	-8133.2%	-593.0%	-462.9%	-159.0%	-46.8%	-90.5%	-88.7%	-82.2%	-62.1%
Net margin	—	—	—	-8036.4%	-588.1%	-488.1%	-181.6%	-59.1%	-105.2%	-98.0%	-52.6%	-134.2%

Returns & leverage

Annual · %

ROE -391.3% ROA -143.7% Debt ratio 370.2%

Show table：Returns & leverage

Item	2012	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
ROE	—	-138.6%	-60.8%	-88.4%	-114.1%	-171.4%	-391.3%	—	—	—	—	—
ROA	—	-109.0%	-55.4%	-71.5%	-68.4%	-62.8%	-64.6%	-40.1%	-49.8%	-47.8%	-37.8%	-143.7%
Debt ratio	—	7.9%	10.1%	28.2%	46.3%	83.1%	83.8%	126.1%	104.7%	156.7%	213.1%	370.2%

EPS

Annual · US$

EPS US$-17.91

Show table：EPS

Item	2012	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	—	—	—	—	-2.02	-1.25	-1.02	-17.91

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Karyopharm Therapeutics Inc. (KPTI) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.